Preclinical testing has suggested that AIR-001 increases functional AAT protein levels and could address the lung and liver manifestations of the disease.

In its third major acquisition in the past six weeks, Gilead is buying a company that will add NaPi2b- and 5T4-targeting agents to its portfolio.

The firm submitted data from the ALKOVE-1 trial, in which neladalkib shrunk tumors in 31 percent of patients and showed promising activity against CNS lesions.

The trial is evaluating how the disclosure of polygenic risk scores for cardiovascular disease affects patients' outcomes.

The firm will use the funds from Oberland Capital for pre-launch activities for its gene therapies for Leber congenital amaurosis type 5 and Best disease.

A study found that in about 10 percent of patients, WGS picked up on clinically actionable information other panels missed.

The firm is clinically testing the dual inhibitor in breast, prostate, colorectal, and lung cancer patients, as Pfizer is also exploring a similar dual-target strategy.

Ahead of the full data release and FDA regulatory decision, doctors and researchers parse the limitations of clinical trials ...

Data from the ATOMIC trial in the NEJM offers a practice-changing adjuvant immuno-chemo regimen for colon cancer, and have experts wondering about a chemo-free option.

Voranigo will be immediately available to patients in England through the Cancer Drugs Fund while the MHRA conducts its regulatory review.

The company is pivoting to the WEE1 inhibitor after halting enrollment on a trial of an ATR inhibitor, formerly its lead program.

Doctors and researchers discussed new broader testing guidelines and changing treatment practices for those with high Lp(a) ...